102 related articles for article (PubMed ID: 3282129)
1. Inhibition, by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD19 monoclonal antibodies.
de Rie MA; Zeijlemaker WP; von dem Borne AE
Leuk Res; 1988; 12(2):135-41. PubMed ID: 3282129
[TBL] [Abstract][Full Text] [Related]
2. Regulatory role of CD19 molecules in B-cell activation and differentiation.
de Rie MA; Schumacher TN; van Schijndel GM; van Lier RA; Miedema F
Cell Immunol; 1989 Feb; 118(2):368-81. PubMed ID: 2463100
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
4. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
6. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
7. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
[TBL] [Abstract][Full Text] [Related]
10. Antibody-induced antigenic modulation is antigen dependent: characterization of 22 proteins on a malignant human B cell line.
Pesando JM; Hoffman P; Abed M
J Immunol; 1986 Dec; 137(11):3689-95. PubMed ID: 3491146
[TBL] [Abstract][Full Text] [Related]
11. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
[TBL] [Abstract][Full Text] [Related]
12. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation.
Pezzutto A; Dörken B; Rabinovitch PS; Ledbetter JA; Moldenhauer G; Clark EA
J Immunol; 1987 May; 138(9):2793-9. PubMed ID: 2437199
[TBL] [Abstract][Full Text] [Related]
13. [Internalization of tumor associated antigen on human lung adenocarcinoma cell line SPC-A-1 by McAb LC-1].
Xie W; Zhang RX; Ge XR
Shi Yan Sheng Wu Xue Bao; 1996 Sep; 29(3):207-19. PubMed ID: 9639808
[TBL] [Abstract][Full Text] [Related]
14. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
15. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human malignant B cells.
Pulczynski S
Leuk Lymphoma; 1994 Oct; 15(3-4):243-52. PubMed ID: 7532507
[TBL] [Abstract][Full Text] [Related]
16. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Int J Cancer; 1990 Mar; 45(3):481-5. PubMed ID: 2307538
[TBL] [Abstract][Full Text] [Related]
17. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins.
May RD; Vitetta ES; Moldenhauer G; Dörken B
Cancer Drug Deliv; 1986; 3(4):261-72. PubMed ID: 2436739
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody.
Vallera DA; Elson M; Brechbiel MW; Dusenbery KE; Burns LJ; Jaszcz WB; Ramsay NK; Panoskaltsis-Mortar A; Kuroki DW; Wagner JE; Vitetta ES; Kersey JH
Cancer Biother Radiopharm; 2004 Feb; 19(1):11-23. PubMed ID: 15068607
[TBL] [Abstract][Full Text] [Related]
19. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study.
Pulczynski S; Boesen AM; Jensen OM
Blood; 1993 Mar; 81(6):1549-57. PubMed ID: 7680920
[TBL] [Abstract][Full Text] [Related]
20. Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms.
Smith SH; Rigley KP; Callard RE
Immunology; 1991 Jul; 73(3):293-7. PubMed ID: 1715315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
